Clicky

Acumen Pharmaceuticals, Inc.(ABOS) News

Date Title
Jul 16 Acumen and JCR partner on brain delivery therapy for Alzheimer’s
Jul 15 Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Tuesday Ahead of Key Market Data
Jul 15 Compass Therapeutics And 2 Other Promising Penny Stocks To Watch
Jul 15 Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery™ Therapy for Alzheimer’s Disease
Jul 15 JCR Pharmaceuticals and Acumen Pharmaceuticals Announce Collaboration to Develop Therapy for Alzheimer’s Disease, Enabled by J-Brain Cargo® Technology Platform
Sep 30 Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference
Sep 26 Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer’s Disease
Sep 25 Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024
Jul 29 Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer’s Disease
Jul 28 Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
Jul 11 Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
Jun 21 Is Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) the Best Halal Stock According to Hedge Funds?
May 15 Acumen Pharmaceuticals Inc (ABOS) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...
May 15 Q1 2024 Acumen Pharmaceuticals Inc Earnings Call
May 14 Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights
May 13 Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
May 8 Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference
May 8 Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease
May 7 Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024
Apr 19 12 Cheap Foods With Anti-Aging Properties That Longevity Scientists Swear By